Skip to menu Skip to content Skip to footer
Dr Yoon An
Dr

Yoon An

Email: 

Overview

Background

Dr Yoon-Kyo An is the “Head of Inflammatory Bowel Disease (IBD)” at Mater Hospital Brisbane and the “Clinical Lead of the IBD Clinical Trials Unit” at Mater Research, a world class centre of clinical and research excellence. The centre is among the largest IBD clinical research units in Australia. She is also a gastroenterologist who specialises in IBD, combining public and private practices at Mater Hospital Brisbane, Mater Private Hospital Brisbane, and Mater Private Hospital Redland. She holds a senior lecturer position at the University of Queensland. Dr An is a co-founder of digital healthcare education platform ‘GutTalk’, which aims to empower patients and communities by closing the communication and knowledge gap in Gut Health.

Dr An completed her Medical Science degree (BMedSc) at the University of Sydney and her Medical degree (MBBS) at the University of Queensland. She undertook her physician and advanced gastroenterology training at the Royal Brisbane and Women’s Hospital and Mater Hospital Brisbane. She completed a clinical and research fellowship in IBD at Mater Hospital Brisbane and completed the executive business and leadership program at the University of Oxford Said Business School. She is currently pursuing a PhD through the University of Queensland and an MBA through Griffith University.

Dr An is a passionate advocate for optimising patient outcomes through a holistic approach to care including personalised treatment plans to manage digestive health and incorporation of clinical and translational research. She is an active IBD clinician and researcher as well as a patient advocate. Her own research focusses on real-world effectiveness of biologic therapy in IBD and the use of intestinal ultrasound to monitor disease activity and predict responses to therapy. She drives collaborative research projects throughout Australia and is actively involved with the Australia New Zealand Inflammatory Bowel Disease Consortium (ANZIBDC), the Gastroenterology Network for Intestinal Ultrasound (GENIUS) and the Gastroenterological Society of Australia (GESA).

Dr An has been successful in competitive research funding from industry and philanthropic organisations. She was the recipient of the inaugural GENIUS fellowship. She has affiliations with many Gastroenterology and IBD societies and has a national presence through her numerous symposia and conference presentations. She also serves on several Medical Advisory Boards including Chiesi, Bristol-Myers Squibb, and NPS Medicine Wise as well as sitting on the Council of Therapeutic Advisory Group. She is a GESA representative on the GP Aware Program committee and works collaboratively with Crohn’s and Colitis Australia (CCA).

Current Appointments

  • 2021 – current: Executive Committee Member – Secretary, ​​​​​​​​​​​​​​ Australia and New Zealand Inflammatory Bowel Disease Consortium (ANZIBDC)
  • 2020 – current: Scientific Committee Member, Australia and New Zealand Inflammatory Bowel Disease Consortium (ANZIBDC)
  • 2020 – current: Board Member – Research Officer, Gastroenterology Network for Intestinal Ultrasound (GENIUS)
  • 2020 – current: Executive Committee Member – IBD Liaison Officer, Young GESA Network, Gastroenterological Society of Australia (GESA)
  • 2020 – current: Expert Advisory Group member, The Council of Therapeutic Advisory Groups (CATAG)
  • 2020 – current: GESA representative, CCA-GESA GP Aware Program Committee, Crohn’s and Colitis Australia (CCA)
  • 2020 – current: Expert Working Group Member, bDMARDs Gastroenterology Design Forum, NPS Medicine Wise
  • 2020 – current: Stakeholder Panel (GESA representative), Value in Prescribing bDMARDs Program, NPS Medicine Wise

Availability

Dr Yoon An is:
Available for supervision

Works

Search Professor Yoon An’s works on UQ eSpace

77 works between 2011 and 2025

41 - 60 of 77 works

2023

Conference Publication

Durability of escalated anti-tumor necrosis factor (TNF) therapy in Crohn's disease is similar between TNF-naive and TNF-experienced patients and may be improved with proactive drug monitoring: An Australian multicenter experience

Gilmore, R., Fernandes, R., Schildkraut, T., Joshi, R., Lin, L., Etchegaray, A., Anandan, A. Shanmuga, Begun, J., An, Y-K and Wright, E. (2023). Durability of escalated anti-tumor necrosis factor (TNF) therapy in Crohn's disease is similar between TNF-naive and TNF-experienced patients and may be improved with proactive drug monitoring: An Australian multicenter experience. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2-5 September 2023. Richmond, VIC Australia: John Wiley & Sons.

Durability of escalated anti-tumor necrosis factor (TNF) therapy in Crohn's disease is similar between TNF-naive and TNF-experienced patients and may be improved with proactive drug monitoring: An Australian multicenter experience

2023

Conference Publication

Upadacitinib for rescue therapy in patients with acute severe ulcerative colitis: An Australian real-world experience

Tan, W. L., Gilmore, R., Huang, A., Fernandes, R., An, Y-K and Begun, J. (2023). Upadacitinib for rescue therapy in patients with acute severe ulcerative colitis: An Australian real-world experience. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2—5 September 2023. Richmond, VIC Australia: John Wiley & Sons.

Upadacitinib for rescue therapy in patients with acute severe ulcerative colitis: An Australian real-world experience

2023

Conference Publication

Australian consensus on ustekinumab in Crohn's disease

Begun, J., An, Y-K, Bryant, R., Christensen, B., Leong, R., Studd, C. and Thin, L. (2023). Australian consensus on ustekinumab in Crohn's disease. HOBOKEN: WILEY.

Australian consensus on ustekinumab in Crohn's disease

2023

Journal Article

Upadacitinib salvage therapy for infliximab experienced patients with acute severe ulcerative colitis

Gilmore, Robert, Tan, Lian, Fernandes, Richard, An, Yoon-Kyo and Begun, Jakob (2023). Upadacitinib salvage therapy for infliximab experienced patients with acute severe ulcerative colitis. Journal of Crohn's and Colitis, 17 (12), 2033-2036. doi: 10.1093/ecco-jcc/jjad115

Upadacitinib salvage therapy for infliximab experienced patients with acute severe ulcerative colitis

2023

Conference Publication

Baseline cytokine levels and microbiome signatures are associted with clinical response following ustekinumab induction in a multi-centre prospective cohort study of crohn's disease patients: results from the aurora study

An, Yoon-Kyo, Lindsay, Niamh, Allan, Natalie, Khoo, Emi, Fernandes, Richard, Amiss, Anna, Pham, Hai, Giri, Rabina, Ooi, Soong-Yuan, Thin, Lena, Lightowler, Daniel, Connor, Susan J., Williams, Astrid-Jane, De Cruz, Peter, Suen, Christopher Li Wai, Kariyawasam, Viraj C., Mitrev, Nikola, Ghaly, Simon, Andrews, Jane M., Christensen, Britt, Sparrow, Miles, White, Lauren S., Bryant, Robert V., Ding, Nik S., Leong, Rupert, Van Langenberg, Daniel R., Seltenreich, Hansjoerg, Subramaniam, Kavitha, Radford-Smith, Graham L. and Begun, Jakob (2023). Baseline cytokine levels and microbiome signatures are associted with clinical response following ustekinumab induction in a multi-centre prospective cohort study of crohn's disease patients: results from the aurora study. Digestive Disease Week (DDW), Chicago, IL United States, 6-9 May 2023. Philadelphia, PA United States: Elsevier. doi: 10.1016/S0016-5085(23)02531-3

Baseline cytokine levels and microbiome signatures are associted with clinical response following ustekinumab induction in a multi-centre prospective cohort study of crohn's disease patients: results from the aurora study

2023

Conference Publication

Post-ustekinumab induction IL-12, IL-23, and ustekinumab levels are associated with clinical response in a multicentre prospective cohort study of Crohn's disease patients: results from the Aurora Study

An, Yoon-Kyo, Lindsay, Niamh, Allan, Natalie, Khoo, Emi, Fernandes, Richard, Amiss, Anna, Pham, Hai, Wong, Kam Fai, Ooi, Soong-Yuan, Thin, Lena, Lightowler, Daniel, Connor, Susan J., Williams, Astrid-Jane, De Cruz, Peter, Suen, Christopher Li Wai, Kariyawasam, Viraj C., Mitrev, Nikola, Ghaly, Simon, Andrews, Jane M., Christensen, Britt, Sparrow, Miles, White, Lauren S., Bryant, Robert V., Ding, Nik S., Leong, Rupert, Van Langenberg, Daniel R., Seltenreich, Hansjoerg, Subramaniam, Kavitha, Radford-Smith, Graham L. and Begun, Jakob (2023). Post-ustekinumab induction IL-12, IL-23, and ustekinumab levels are associated with clinical response in a multicentre prospective cohort study of Crohn's disease patients: results from the Aurora Study. Digestive Disease Week (DDW), Chicago, IL United States, 6-9 May 2023. Philadelphia, PA United States: Elsevier.

Post-ustekinumab induction IL-12, IL-23, and ustekinumab levels are associated with clinical response in a multicentre prospective cohort study of Crohn's disease patients: results from the Aurora Study

2023

Conference Publication

Reduction of bowel wall thickness and doppler signals as eary as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of acute severe ulcerative colitis: USUC study including genius cohort

An, Yoon-Kyo, Fernandes, Richard, Lindsay, Niamh, Khoo, Emi, Pham, Hai, Wong, Kam Fai, Thin, Lena, Goodsall, Thomas, Bryant, Robert V., Wright, Emily K., Smith, Rebecca, Friedman, Antony and Begun, Jakob (2023). Reduction of bowel wall thickness and doppler signals as eary as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of acute severe ulcerative colitis: USUC study including genius cohort. Digestive Disease Week (DDW) 2023, Chicago, IL United States, 6-9 May 2023. Philadelphia, PA United States: Elsevier. doi: 10.1016/s0016-5085(23)03032-9

Reduction of bowel wall thickness and doppler signals as eary as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of acute severe ulcerative colitis: USUC study including genius cohort

2023

Conference Publication

Post-Ustekinumab induction IL-12, IL-13 and Ustekinumab levels are associated with clinical response in a multicentre prospective cohort study of Crohn's disease patients: results from the Aurora study

An, Yoon-Kyo, Lindsay, Niamh, Allan, Natalie, Khoo, Emi, Fernandes, Richard, Amiss, Anna, Pham, Hai, Wong, Kam Fai, Ooi, Soong-Yuan, Thin, Lena, Lightowler, Daniel, Connor, Susan J., Williams, Astrid-Jane, De Cruz, Peter, Suen, Christopher Li Wai, Kariyawasam, Viraj C., Mitrev, Nikola, Ghaly, Dr Simon, Andrews, Jane M., Christensen, Britt, Sparrow, Miles, White, Lauren S., Bryant, Robert V., Ding, Nik S., Leong, Rupert, Van Langenberg, Daniel R., Seltenreich, Hansjoerg, Subramaniam, Kavitha, Radford-Smith, Graham L. and Begun, Jakob (2023). Post-Ustekinumab induction IL-12, IL-13 and Ustekinumab levels are associated with clinical response in a multicentre prospective cohort study of Crohn's disease patients: results from the Aurora study. Digestive Disease Week DDW / AGA Conference 2023, Chicago, IL United States, 6-9 May 2023. Philadelphia, PA United States: Elsevier. doi: 10.1016/s0016-5085(23)03564-3

Post-Ustekinumab induction IL-12, IL-13 and Ustekinumab levels are associated with clinical response in a multicentre prospective cohort study of Crohn's disease patients: results from the Aurora study

2023

Conference Publication

Withdrawal Versus Continuation Of Thiopurine In Vedolizumab-treated Patients With Ulcerative Colitis (Views): A Multi-centre Randomised Controlled Trial

Pudipeddi, Aviv, Paramsothy, Sudarshan, Kariyawasam, Viraj C., Paramsothy, Ramesh, Ghaly, Dr Simon, Haifer, Craig, An, Yoon-Kyo, Begun, Jakob, Connor, Susan J., Corte, Crispin, Ward, Mark, De Cruz, Peter, Fung, Caroline, Chan, Pak Wo, Mourad, Fadi H., Redmond, Diane and Leong, Rupert (2023). Withdrawal Versus Continuation Of Thiopurine In Vedolizumab-treated Patients With Ulcerative Colitis (Views): A Multi-centre Randomised Controlled Trial. Digestive Disease Week (DDW) 2023, Chicago, IL United States, 6-9 May 2023. Philadelphia, PA United States: Elsevier. doi: 10.1016/s0016-5085(23)01488-9

Withdrawal Versus Continuation Of Thiopurine In Vedolizumab-treated Patients With Ulcerative Colitis (Views): A Multi-centre Randomised Controlled Trial

2023

Conference Publication

Reduction of bowel wall thickness and doppler signals as eary as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of acute severe ulcerative colitis: USUC study including genius cohort

An, Yoon-Kyo, Fernandes, Richard, Lindsay, Niamh, Khoo, Emi, Pham, Hai, Wong, Kam Fai, Thin, Lena, Goodsall, Thomas, Bryant, Robert V., Wright, Emily K., Smith, Rebecca, Friedman, Antony and Begun, Jakob (2023). Reduction of bowel wall thickness and doppler signals as eary as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of acute severe ulcerative colitis: USUC study including genius cohort. Digestive Disease Week (DDW), Chicago, IL United States, 6-9 May 2023. Philadelphia, PA United States: Elsevier.

Reduction of bowel wall thickness and doppler signals as eary as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of acute severe ulcerative colitis: USUC study including genius cohort

2023

Conference Publication

WITHDRAWAL VERSUS CONTINUATION OF THIOPURINE IN VEDOLIZUMAB-TREATED PATIENTS WITH ULCERATIVE COLITIS (VIEWS): A MULTI-CENTRE RANDOMISED CONTROLLED TRIAL

Pudipeddi, Aviv, Paramsothy, Sudarshan, Kariyawasam, Viraj C., Paramsothy, Ramesh, Ghaly, Dr Simon, Haifer, Craig, An, Yoon-Kyo, Begun, Jakob, Connor, Susan J., Corte, Crispin, Ward, Mark, De Cruz, Peter, Fung, Caroline, Chan, Pak Wo, Mourad, Fadi H., Redmond, Diane and Leong, Rupert (2023). WITHDRAWAL VERSUS CONTINUATION OF THIOPURINE IN VEDOLIZUMAB-TREATED PATIENTS WITH ULCERATIVE COLITIS (VIEWS): A MULTI-CENTRE RANDOMISED CONTROLLED TRIAL. Digestive Disease Week (DDW), Chicago Il, May 06-09, 2023. PHILADELPHIA: W B SAUNDERS CO-ELSEVIER INC.

WITHDRAWAL VERSUS CONTINUATION OF THIOPURINE IN VEDOLIZUMAB-TREATED PATIENTS WITH ULCERATIVE COLITIS (VIEWS): A MULTI-CENTRE RANDOMISED CONTROLLED TRIAL

2023

Conference Publication

Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn's disease patients: results from the AURORA Study including ANZIBDC Cohort

An, Y. K., Lindsay, N., Allan, N., Khoo, E., Fernandes, R., Amiss, A., Pham, H., Wong, K. F., Ooi, S. Y., Thin, L., Lightowler, D., Connor, S. J., Williams, A. J., De Cruz, P., Suen, C. Li Wai, Kariyawasam, V., Mitrev, N., Ghaly, S., Andrews, J. M., Christensen, B., Sparrow, M. P., White, L. S., Bryant, R. V., Ding, N., Leong, R., Van Langenberg, D., Seltenreich, H., Subramaniam, K., Radford-Smith, G. and Begun, J. (2023). Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn's disease patients: results from the AURORA Study including ANZIBDC Cohort. 18th Congress of ECCO, Copenhagen, Denmark, 1-4 March 2023. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjac190.0793

Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn's disease patients: results from the AURORA Study including ANZIBDC Cohort

2023

Conference Publication

Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trial

Pudipeddi, A., Paramsothy, S., Kariyawasam, V., Paramsothy, R., Ghaly, S., Haifer, C., An, Y. K., Begun, J., Connor, S., Corte, C., Ward, M., De Cruz, P., Fung, C., Redmond, D. and Leong, R. W. (2023). Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trial. OXFORD: OXFORD UNIV PRESS.

Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trial

2023

Conference Publication

Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trial

Pudipeddi, A., Paramsothy, S., Kariyawasam, V., Paramsothy, R., Ghaly, S., Haifer, C., An, Y. K., Begun, J., Connor, S., Corte, C., Ward, M., De Cruz, P., Fung, C., Redmond, D. and Leong, R. W. (2023). Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trial. 18th Congress of ECCO, Copenhagen, Denmark, 1-4 March 2023. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjac190.0543

Withdrawal versus continuation of thiopurine in vedolizumab-treated patients with Ulcerative Colitis (VIEWS): a multi-centre randomised controlled trial

2023

Conference Publication

Reduction of bowel wall thickness and doppler signals as early as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of Acute Severe Ulcerative Colitis: USUC Study including the GENIUS cohort

An, Y. K., Fernandes, R., Lindsay, N., Khoo, E., Pham, H., Wong, K. F., Thin, L., Goodsall, T., Bryant, R. V., Wright, E., Smith, R., Friedman, A., Begun, J. and Gastroenterology Network of Intestinal Ultrasound (GENIUS) (2023). Reduction of bowel wall thickness and doppler signals as early as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of Acute Severe Ulcerative Colitis: USUC Study including the GENIUS cohort. 18th Congress of ECCO, Copenhagen, Denmark, 1-4 March 2023. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjac190.0744

Reduction of bowel wall thickness and doppler signals as early as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of Acute Severe Ulcerative Colitis: USUC Study including the GENIUS cohort

2022

Journal Article

Refractory fulminant colitis following ocrelizumab therapy requiring colectomy in a patient with multiple sclerosis

Malloy, Reuben, Fernandes, Richard, Begun, Jakob and An, Yoon-Kyo (2022). Refractory fulminant colitis following ocrelizumab therapy requiring colectomy in a patient with multiple sclerosis. BMJ Case Reports, 15 (12) 252140, e252140. doi: 10.1136/bcr-2022-252140

Refractory fulminant colitis following ocrelizumab therapy requiring colectomy in a patient with multiple sclerosis

2022

Conference Publication

Post-induction IL-12/23 levels correlate with clinical response and remission after ustekinumab in a multicenter prospective cohort study of patients with Crohn’s disease: Preliminary induction results of the AURORA study, including the Australia New Zealand IBD Consortium Cohort

An,Yoon-Kyo, Lindsay, Niamh, Allan, Natalie, Khoo, Emi, Amiss, Anna, Moniruzzaman, Md, Fernandes, Richard, Ooi, Soong-Yuan J., Thin, Lena W.Y., Mstj, Daniel Lightowler, Connor, Susan, Williams, Astrid-Jane, De Cruz, Peter, Suen, Christopher Li Wai, Kariyawasam, Viraj C., Mitrev, Nicola, Ghaly, Simon, Andrews, Jane M., Christensen, Britt, Sparrow, Miles, White, Lauren, Bryant, Robert, Ding, Nik S., Leong, Rupert W., Van Langenberg, Daniel R., Seltenreich, Hans, Subramaniam, Kavitha, Radford-Smith, Graham and Begun, Jakob (2022). Post-induction IL-12/23 levels correlate with clinical response and remission after ustekinumab in a multicenter prospective cohort study of patients with Crohn’s disease: Preliminary induction results of the AURORA study, including the Australia New Zealand IBD Consortium Cohort. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2022, Sydney, NSW Australia, 9–11 September 2022. Richmond, VIC Australia: John Wiley & Sons. doi: 10.1111/jgh.15953

Post-induction IL-12/23 levels correlate with clinical response and remission after ustekinumab in a multicenter prospective cohort study of patients with Crohn’s disease: Preliminary induction results of the AURORA study, including the Australia New Zealand IBD Consortium Cohort

2022

Conference Publication

Histological Remission Using A Nancy Index Of 0 Is Associated With Longer Relapse-free Survival Than Histological Activity In Patients With Ulcerative Colitis In Clinical And Endoscopic Remission

Pudipeddi, Aviv, Fung, Caroline, Kariyawasam, Viraj, Paramsothy, Ramesh, Ghaly, Simon, Haifer, Craig, An, Yoon, Begun, Jakob, Connor, Susan, Chetwood, John, Paramsothy, Sudarshan and Leong, Rupert (2022). Histological Remission Using A Nancy Index Of 0 Is Associated With Longer Relapse-free Survival Than Histological Activity In Patients With Ulcerative Colitis In Clinical And Endoscopic Remission. International Digestive Disease Forum (IDDF), Hong Kong, China, 2-4 September 2022. London, United Kingdom: BMJ Group. doi: 10.1136/gutjnl-2022-IDDF.207

Histological Remission Using A Nancy Index Of 0 Is Associated With Longer Relapse-free Survival Than Histological Activity In Patients With Ulcerative Colitis In Clinical And Endoscopic Remission

2021

Journal Article

Higher anti-tumor necrosis factor-α levels correlate with improved radiological outcomes in Crohn's perianal fistulas

De Gregorio, Michael, Lee, Tanya, Krishnaprasad, Krupa, Amos, Gregory, An, Yoon-Kyo, Bastian-Jordan, Matthew, Begun, Jakob, Borok, Nira, Brown, Dougal J. M., Cheung, Wa, Connor, Susan J., Gerstenmaier, Jan, Gilbert, Lauren E., Gilmore, Robert, Gu, Bonita, Kutaiba, Numan, Lee, Allan, Mahy, Gillian, Srinivasan, Ashish, Thin, Lena, Thompson, Alexander J., Welman, Christopher J., Yong, Eric X. Z., De Cruz, Peter, van Langenberg, Daniel, Sparrow, Miles P. and Ding, Nik S. (2021). Higher anti-tumor necrosis factor-α levels correlate with improved radiological outcomes in Crohn's perianal fistulas. Clinical Gastroenterology and Hepatology, 20 (6), 1306-1314. doi: 10.1016/j.cgh.2021.07.053

Higher anti-tumor necrosis factor-α levels correlate with improved radiological outcomes in Crohn's perianal fistulas

2021

Conference Publication

Higher anti-tumour necrosis factor-alpha drug levels are associated with improved radiological outcomes in patients with perianal fistulising Crohn’s disease: A retrospective multi-centre study

De Gregorio, M., Lee, T., Krishnaprasad, K., Amos, G., An, Y. K., Bastian-Jordan, M., Begun, J., Borok, N., Brown, D. J. M., Cheung, W., Connor, S., Gerstenmaier, J., Gilbert, L. E., Gilmore, R., Gu, B., Kutaiba, N., Lee, A., Mahy, G., Srinivasan, A., Thin, L., Thompson, A., Welman, C. J., Yong, E. X., De Cruz, P., van Langenberg, D., Sparrow, M. and Ding, N. S. (2021). Higher anti-tumour necrosis factor-alpha drug levels are associated with improved radiological outcomes in patients with perianal fistulising Crohn’s disease: A retrospective multi-centre study. 16th Congress of ECCO, Online, 2-3 & 8-10 July 2021. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjab076.523

Higher anti-tumour necrosis factor-alpha drug levels are associated with improved radiological outcomes in patients with perianal fistulising Crohn’s disease: A retrospective multi-centre study

Supervision

Availability

Dr Yoon An is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Media

Enquiries

For media enquiries about Dr Yoon An's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au